Look Under The Hood: PBE Has 27% Upside
October 10, 2024 at 12:20 PM EDT
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Biotechnology & Genome ETF (PBE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $86.04 per unit.
